Vaughan Nelson Investment Management L.P. Acquires 1,470 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Vaughan Nelson Investment Management L.P. lifted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 32.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,010 shares of the medical research company’s stock after purchasing an additional 1,470 shares during the period. Vaughan Nelson Investment Management L.P.’s holdings in Bio-Rad Laboratories were worth $2,079,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in Bio-Rad Laboratories by 2.0% during the fourth quarter. Vanguard Group Inc. now owns 2,389,889 shares of the medical research company’s stock worth $771,671,000 after buying an additional 46,119 shares in the last quarter. Earnest Partners LLC grew its position in Bio-Rad Laboratories by 25.6% during the third quarter. Earnest Partners LLC now owns 351,510 shares of the medical research company’s stock worth $125,999,000 after buying an additional 71,570 shares in the last quarter. Thompson Siegel & Walmsley LLC grew its position in Bio-Rad Laboratories by 11.5% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 348,473 shares of the medical research company’s stock worth $112,518,000 after buying an additional 35,890 shares in the last quarter. Parnassus Investments LLC grew its position in Bio-Rad Laboratories by 7.7% during the fourth quarter. Parnassus Investments LLC now owns 237,790 shares of the medical research company’s stock worth $76,780,000 after buying an additional 16,999 shares in the last quarter. Finally, Norges Bank acquired a new stake in Bio-Rad Laboratories during the fourth quarter worth about $73,142,000. 65.24% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on BIO. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Tuesday, May 28th. UBS Group dropped their target price on Bio-Rad Laboratories from $420.00 to $385.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Citigroup lowered Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and decreased their price target for the company from $400.00 to $365.00 in a research note on Wednesday, April 3rd. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $315.00 price objective (down from $440.00) on shares of Bio-Rad Laboratories in a research note on Monday, June 3rd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $436.67.

Insider Activity

In related news, EVP Michael Crowley sold 369 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $281.91, for a total value of $104,024.79. Following the completion of the transaction, the executive vice president now owns 6,573 shares in the company, valued at approximately $1,852,994.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 17.50% of the stock is owned by insiders.

Bio-Rad Laboratories Trading Up 1.4 %

Shares of BIO opened at $267.55 on Wednesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.89 and a current ratio of 6.57. The company has a market cap of $7.63 billion, a price-to-earnings ratio of -25.83 and a beta of 0.93. The stock has a fifty day moving average price of $283.34 and a two-hundred day moving average price of $309.88. Bio-Rad Laboratories, Inc. has a 52-week low of $261.59 and a 52-week high of $431.79.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Tuesday, May 7th. The medical research company reported $2.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.04 by $0.25. The business had revenue of $610.82 million during the quarter, compared to analysts’ expectations of $619.09 million. Bio-Rad Laboratories had a positive return on equity of 3.59% and a negative net margin of 12.37%. The firm’s revenue for the quarter was down 9.8% compared to the same quarter last year. During the same period in the previous year, the business posted $3.34 earnings per share. Analysts predict that Bio-Rad Laboratories, Inc. will post 10.8 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.